Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019

Bedin, Anne‐Sophie; Makinson, Alain; Picot, Marie‐Christine; Mennechet, Frank; Malergue, Fabrice; Pisoni, Amandine; Nyiramigisha, Esperance; Montagnier, Lise; Bolloré, Karine; Debiesse, Ségolène; Morquin, David; Veyrenche, Nicolas; Renault, Constance; Foulongne, Vincent; Bret, Caroline; Bourdin, Arnaud; Moing, Vincent Le; Perre, Philippe Van de; Tuaillon, Edouard

doi:10.1093/infdis/jiaa724

Cited by 48 publications

(50 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both CD64N and CD169Mo ratios were able to detect ACov-2 and ABI better than the current biochemical parameters used in clinical routine to discern between acute viral or bacterial infection. The present work shows a cut-off value of 3.3 in both biomarkers, very similar to that described previously ( 14 ). However, this assay is not specific to ACov-2 infection since CD169Mo was increased in acute parainfluenza, human respiratory syncytial, and C-hepatitis virus infections at emergency units ( 12 , 15 ).…”

Section: Discussionsupporting

confidence: 90%

Validation of a Quick Flow Cytometry-Based Assay for Acute Infection Based on CD64 and CD169 Expression. New Tools for Early Diagnosis in COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

Objectives: Several parameters aid in deciphering between viral and bacterial infections; however, new tools should be investigated in order to reduce the time to results and proceed with an early target-therapy. Validation of a biomarker study, including CD64 and CD169 expression, was conducted.Material and Methods: Patients with active SARS-CoV-2 infection (ACov-2), bacterial infection (ABI), healthy controls, and antiretroviral-controlled chronic HIV infection were assessed. Whole blood was stained and, after lysing no-wash protocol, acquired by flow cytometry. The median fluorescence intensity (MFI) of CD64 and CD169 was measured in granulocytes, monocytes, and lymphocytes. The CD64 MFI ratio granulocytes to lymphocytes (CD64N) and CD169 MFI ratio monocytes to lymphocytes (CD169Mo) were evaluated as biomarkers of acute bacterial and viral infection, respectively.Results: A CD64N ratio higher than 3.3 identified patients with ABI with 83.3 and 85.9% sensitivity and specificity, with an area under the curve (AUC) of 83.5%. In contrast, other analytic or hematological parameters used in the clinic had lower AUC compared with the CD64N ratio. Moreover, a CD169Mo ratio higher than 3.3 was able to identify ACov-2 with 91.7 and 89.8 sensitivity and specificity, with the highest AUC (92.0%).Conclusion: This work confirms the previous data of CD64N and CD169Mo ratios in an independent cohort, including controlled chronic viral HIV infection patients as biomarkers of acute bacterial and viral infections, respectively. Such an approach would benefit from quick pathogen identification for a direct-therapy with a clear application in different Health Care Units, especially during this COVID pandemic.

show abstract

Section: Discussionsupporting

confidence: 90%

Validation of a Quick Flow Cytometry-Based Assay for Acute Infection Based on CD64 and CD169 Expression. New Tools for Early Diagnosis in COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Our analysis showed an increase in SIGLEC1 in CD16+ monocytes from COVID-19 cases compared to healthy cases, as well as when comparing mild cases to healthy controls. A recent study reported increased expression of sialoadhesin on total monocytes as measured by flow cytometry from people with COVID-19 compared to healthy controls (53). Another flow cytometry study reported increased CD169/SIGLEC1 protein expression on total monocytes from COVID-19 cases with mild disease compared to those with severe disease (54).…”

Section: Discussionmentioning

confidence: 99%

Transcriptional Changes in CD16+ Monocytes May Contribute to the Pathogenesis of COVID-19

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has caused more than three million deaths globally. The severity of the disease is characterized, in part, by a dysregulated immune response. CD16+ monocytes are innate immune cells involved in inflammatory responses to viral infections, and tissue repair, among other functions. We characterized the transcriptional changes in CD16+ monocytes from PBMC of people with COVID-19, and from healthy individuals using publicly available single cell RNA sequencing data. CD16+ monocytes from people with COVID-19 compared to those from healthy individuals expressed transcriptional changes indicative of increased cell activation, and induction of a migratory phenotype. We also analyzed COVID-19 cases based on severity of the disease and found that mild cases were characterized by upregulation of interferon response and MHC class II related genes, whereas the severe cases had dysregulated expression of mitochondrial and antigen presentation genes, and upregulated inflammatory, cell movement, and apoptotic gene signatures. These results suggest that CD16+ monocytes in people with COVID-19 contribute to a dysregulated host response characterized by decreased antigen presentation, and an elevated inflammatory response with increased monocytic infiltration into tissues. Our results show that there are transcriptomic changes in CD16+ monocytes that may impact the functions of these cells, contributing to the pathogenesis and severity of COVID-19.

show abstract

“…Engineered sequence performed on Sp in positions 21,840 to 21,855 of the COVID-19 sequence MN908947, showed a 15-bases match to the envelope glycoproteins (Envs) of the HIV-1 [19]. According to Luc Montagnier study group, the significant engineered sequences, are all crucial for the penetration into the cells of the human lungs [22]. So, it would be legitimate to assume that the use of MSCs might contribute not only to reduce the invasiveness and the aggressiveness of SARS-CoV-2, but should be also considered a valid tool in immunocompromised COVID-19 patients, as they would preclude any viral changes, which implies the formation of a reservoir of unresponsive molecules and factors towards endogenous immune inhibitors [20,[23][24][25][26][27][28].…”

Section: Present Procedures and Future Perspectives And Limitationsmentioning

confidence: 99%

Mesenchymal Stem Cells: The Secret Children’s Weapons against the SARS-CoV-2 Lethal Infection

et al. 2021

View full text Add to dashboard Cite

Due to the promising effects of mesenchymal stem cells (MSCs) in the treatment of various diseases, this commentary aimed to focus on the auxiliary role of MSCs to reduce inflammatory processes of acute respiratory infections caused by the 2019 novel coronavirus (COVID-19). Since early in 2020, COVID-19, a consequence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly affected millions of people world-wide. The SARS-CoV-2 infection in children appears to be an unusual event. Despite the high number of affected adult and elderly, children and adolescents remained low in amounts, and marginally touched. Based on the promising role of cell therapy and regenerative medicine approaches in the treatment of several life-threatening diseases, it seems that applying MSCs cell-based approaches can also be a hopeful strategy for improving subjects with severe acute respiratory infections caused by COVID-19.

show abstract

Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019

Cited by 48 publications

References 9 publications

Validation of a Quick Flow Cytometry-Based Assay for Acute Infection Based on CD64 and CD169 Expression. New Tools for Early Diagnosis in COVID-19 Pandemic

Validation of a Quick Flow Cytometry-Based Assay for Acute Infection Based on CD64 and CD169 Expression. New Tools for Early Diagnosis in COVID-19 Pandemic

Transcriptional Changes in CD16+ Monocytes May Contribute to the Pathogenesis of COVID-19

Mesenchymal Stem Cells: The Secret Children’s Weapons against the SARS-CoV-2 Lethal Infection

Contact Info

Product

Resources

About